Rizatriptan, sold under the brand name Maxalt among others, is a medication used for the treatment of migraine headaches. It is taken by mouth. It can also be applied on the tongue. It is a serotonin 1B/1D receptor agonist. Common side effects include che st discomfort, dizziness, somnolence, fatigue and paresthesia; more technical information includes that rizatriptan is formulated as a benzoate salt available as conventional tablets and orally disintegrating tablets, achieves peak plasma concentrations within about 1 to 2 hours, has an elimination half life on the order of 2 to 3 hours, and is primarily metabolized via monoamine oxidase A to inactive metabolites with a low plasma protein binding fraction; clinically relevant pharmacokinetic interactions include increased exposure with propranolol and contraindications with monoamine oxidase inhibitors and certain serotonergic agents because of the risk of serotonin syndrome.
Parent: Rizatriptan
Parent: Rizatriptan
Parent: Rizatriptan/ N-Nitroso
![N,N,N-Trimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanaminium Chloride](https://veeprho.com/wp-content/uploads/2025/01/VE0022780-N-N-N-Trimethyl-2-5-1H-1-2-4-triazol-1-ylmethyl.png "N,N,N-Trimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanaminium Chloride")
Parent: Rizatriptan
Parent: Rizatriptan
Parent: Rizatriptan / Rizatriptan Benzoate
Parent: Rizatriptan
Parent: Rizatriptan
Parent: Rizatriptan
Parent: Rizatriptan
Parent: Rizatriptan
![2-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]Methyl] Rizatriptan Benzoate](https://veeprho.com/wp-content/uploads/2025/09/VE0025331-2-3-2-Dimethylamino-ethyl-1H-indol-5-yl-Methyl-Rizatriptan-Benzoate.png "2-[[3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl]Methyl] Rizatriptan Benzoate")
Parent: Rizatriptan
For active pharmaceutical ingredient control, rizatriptan related compounds and process impurities are monitored by validated stability indicating methods such as HPLC with mass spectrometric confirmation and by NMR when needed; typical quality specifications adopt ICH informed limits where individual specified impurities are controlled at low levels, commonly below 0.10 to 0.20 percent of the API and total impurities are limited to a fraction of a percent, with thresholds for reporting and identification set per regulatory guidance; common identified related substances reported from synthesis and degradation studies include N-desmethyl rizatriptan, hydroxylated positional isomers, potential N-oxide species, trace process residuals from coupling or protecting group steps and residual solvents, and these are characterized, quantified and controlled to ensure safety and stability.
Rizatriptan is used for the acute treatment of migraine attacks with or without aura to relieve headache pain and associated symptoms; it is not indicated for migraine prevention.
No, rizatriptan is not a narcotic; it is a selective serotonin 1B/1D receptor agonist and does not have the opioid pharmacology associated with narcotics.
Avoid using another triptan or an ergotamine containing drug within 24 hours, avoid monoamine oxidase inhibitors and uncontrolled hypertension, and use caution with concomitant serotonergic antidepressants due to serotonin syndrome risk; consult prescribing information for specific interaction details.
No, rizatriptan is not a nerve blocker in the sense of local anesthetics or nerve conduction blockers; it acts centrally and cranially as a 5-HT1B/1D receptor agonist to constrict cranial blood vessels and inhibit trigeminal neurotransmitter release.
